TVM Capital Life Science’s investment professionals draw upon the experience, international approach and demonstrated success of about 100 exits from our portfolio. These exits include about 100 initial public offerings on the NASDAQ and various European Exchanges and multiple trade sales and mergers.
With more than two decades of experience in picking promising entrepreneurs, concepts and products for development, and building successful entrepreneurial companies, we are acutely aware of what it takes to build a world class technology, product or company, and astute at supporting management teams to bring companies and projects to value inflection points.
Our most recent funds TVM Life Science Innovation I and TVM Life Science Innovation II focus on a dedicated investment approach to developing early-stage pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies.
Besides this, we are actively seeking investments in innovative later-stage biopharma, diagnostic, medtech and digital-health companies in Europe, North America and Asia.
Among others, TVM Capital Life Science was the Series A lead investor in the following publicly listed companies with market capitalizations that at some point were or still are greater than roughly €1 billion: Qiagen, Colucid, Sequenom, Actelion and Intercell. TVM Capital Life Science also led the Series A investments in Direvo and Jerini, the largest M&A transactions in the history of German biotechnology. And we are also proud to have been investors in companies such as Morphosys, Evotec, Idenix and Pharmasset, ‘household names’ for drug discovery in the pharmaceutical industry today.